Molecular cloning is the laboratory process of copying a specific piece of DNA and inserting it into a carrier so it can be grown, studied, or used to make proteins. Think of it as photocopying a single recipe into a cookbook so chefs can reproduce the same dish reliably. For investors, cloning is a foundational tool that enables the development, testing and manufacture of therapies, diagnostics and biologic products, influencing timelines, costs, patent position and commercial potential.
gibson assemblymedical
Gibson Assembly is a laboratory method that uses a mix of enzymes to join multiple pieces of DNA into a single continuous sequence in one step, like gluing puzzle pieces so they fit seamlessly. For investors, it matters because it speeds and simplifies genetic engineering work, reducing research time and cost, enabling faster product development, stronger intellectual property, and potentially improving a biotech company’s competitive edge and valuation.
restriction/ligationmedical
Restriction/ligation is a basic laboratory process used to cut DNA at specific spots (restriction) and then join pieces back together (ligation), like using scissors to trim a ribbon and glue to stick pieces into a new shape. Investors should care because it’s a foundational step in creating genetically modified cells, research tools, or therapeutic candidates; successful use or protection of this technique can affect a biotech project’s progress, costs, timelines and intellectual property value.
sanger sequencingmedical
Sanger sequencing is a laboratory method for reading the order of DNA building blocks, producing a precise short “text” of genetic letters. Investors care because it’s a foundational tool used to confirm genetic targets, validate diagnostic tests, ensure quality control in biologic manufacturing, and support research that can lead to drugs or medical tests—much like a proofreader catching critical typos before publication.
multi-tenant saastechnical
Multi-tenant SaaS is a cloud software delivery model where a single instance of an application and its underlying infrastructure serves many customers at once, with each customer’s data kept separate. Think of it like an apartment building where residents share the same utilities but have private units. Investors care because this design usually lowers costs, speeds product updates, and makes revenue more predictable and scalable, affecting margins and long-term growth potential.
machine learningtechnical
Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.
bioregistrationtechnical
Bioregistration is the regulatory process by which biological medicines, vaccines, or cellular and gene therapies are reviewed and officially authorized for sale by health authorities. For investors it is a critical milestone because receiving registration unlocks the ability to commercialize a product, reduces technical and regulatory risk, and sets expected timelines and revenue potential—much like a building permit that lets a construction project move from plans to open doors.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
Scalable collaboration for biotech and pharma teams: Enables high-throughput construct design (up to 1,000 constructs) with real-time data sharing
Integrated, AI-ready biologics ecosystem: Connects design to execution through native Signals One platform integration and cloud-native infrastructure
Unified molecular cloning workflows: Supports Golden Gate, Gibson assembly, restriction/ligation, primer design, and sequencing analysis in one platform
WALTHAM, Mass.--(BUSINESS WIRE)--
Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining essential cloning methodologies with enterprise-grade collaboration.
The Signals BioDesign offering provides a complete solution for designing therapeutic constructs across core cloning workflows including Golden Gate, Gibson assembly, and restriction/ligation, plus primer design, Sanger sequencing analysis, and protein translation in one simple to use application. The solution enables high-throughput combinatorial cloning for up to 1,000 constructs while maintaining workflow simplicity, allowing pharma and biotech researchers to design faster, collaborate seamlessly, and eliminate costly data silos. As the only cloud-native molecular cloning tool with integration in the Signals OneTM platform, the Signals BioDesign solution connects design with existing bioregistration and multi-modal experiment capture in a unified biologics research ecosystem.
"The Signals BioDesign offering addresses a critical need for molecular biology teams developing the next generation of antibody, cell, and gene therapies," said Kevin Willoe, president of Revvity Signals Software. "This solution empowers researchers with enterprise-ready collaboration and centralized construct management without the complexity of over-engineered platforms. By integrating directly with our Signals One platform, we're focusing on enabling teams to accelerate therapeutic development timelines and bring life-saving treatments to patients faster."
The cloud-native architecture enables real-time team collaboration, centralized bio-sequence libraries, duplicate checking, monomer management, and granular access controls that desktop tools cannot provide, while multi-tenant SaaS deployment eliminates the administrative overhead and compliance risks associated with desktop software licensing. The Signals BioDesign solution’s AI-ready data infrastructure also positions research teams for future machine learning applications in sequence optimization and predictive design.
Revvity will introduce the Signals BioDesign offering at the Bio-IT World Conference & Expo, May 19-21, in Boston, Massachusetts.
About Revvity
At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
